Pharma

Your Article Summary

See Latest Articles

Active Biotech AB Interim report January-June 2009
Active Biotech, 08/07/09

In June, it was announced that laquinimod's second pivotal clinical Phase III trial for the treatment of RRMS, BRAVO, had been fully enrolled following the inclusion of more than 1,200 patients. BRAVO is a global clinical trial aimed at evaluating the efficiency, safety and tolerability of laquinimod compared with placebo, and will also provide risk–benefit data for laquinimod, compared with an injected RRMS product currently available on the market, Avonex.

Today in Biotechnology...keeping you current

Receive free subspecialty "5-minute updates" via email

What Makes a Generic Medication Generic?
Journal of Psychosocial Nursing and Mental Health Services, 12/18/09

Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09

Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09

 See all of Biotechnology